Proteomedix, the Swiss cancer diagnostics company and Dynex Technologies, announce today a strategic partnership enabling Proteomedix to establish automated workflows for their prostate cancer diagnostics test and sell Dynex instruments to the global clinical market. The partnership builds on the longstanding relationship between both companies with Dynex Technologies’ industry proven automated ELISA instrumentation and Proteomedix’ Proclarix for prostate cancer diagnosis.
Dynex’s range of automation systems offers perfect solutions for Proteomedix’ customers. With an instrument base of over 7,500 systems globally, Dynex has a proven track record of quality, acceptance and success in developing instruments for automating clinical assays. Designed with automated clinical laboratory workflows in mind, Proclarix was clinically validated on the Dynex DSX platform. Protocols for the DS2, and Agility platforms will be made available in the near future.
“Proteomedix and Dynex have worked together for a number of years during the development and clinical validation phase of Proclarix. Now that we are directly selling and supporting Proclarix in conjunction with the Dynex automation systems, Proteomedix is well positioned to offer laboratory customers a single point of contact, full solution for their automated testing needs, improving the installation, training and implementation process. With multiple instrument offerings customers can choose a “right-sized” instrument that fits their needs.” said Helge Lubenow, CEO of Proteomedix.
“Partnering with Proteomedix aligns with our initiatives to drive growth of our core product line by leveraging partnerships to offer a growing menu of applications in the specialty oncology space” remarked David Sholehvar, MD, CEO of Dynex Technologies. “Proteomedix has a very exciting product offering and pipeline. Our mutual commitment to excellence will most certainly drive value for our customers."